Australia markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
55.48-0.49 (-0.88%)
At close: 04:00PM EDT
55.19 -0.29 (-0.52%)
After hours: 05:16PM EDT

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees18,000

Key executives

NameTitlePayExercisedYear born
Mr. John J. Greisch M.B.A.Executive Chairman of the Board125.91kN/A1955
Mr. Alessandro MaselliPresident, CEO & Director1.08MN/A1972
Dr. Aristippos Gennadios Ph.D.Group President of Pharma & Consumer Health Segment799.26kN/A1966
Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of Staff622.12kN/A1977
Mr. Matti M. MasanovichSenior VP & CFON/AN/A1972
Mr. Michael J. Hatzfeld Jr.VP & Chief Accounting OfficerN/AN/A1973
Mr. Charles LickfoldSenior VP & Chief Information OfficerN/AN/A1974
Mr. Paul SurdezVice President of Investor RelationsN/AN/AN/A
Mr. Joseph A. Ferraro J.D.Senior VP, General Counsel, Chief Compliance Officer & Corporate SecretaryN/AN/A1978
Mr. Michael J. GrippoSenior Vice President of Strategy & Corporate DevelopmentN/AN/A1969
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Corporate governance

Catalent, Inc.’s ISS governance QualityScore as of 1 June 2024 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.